Top

Published in:

01-02-2015 | Original article

3’-Deoxy-3’-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer

Comparison with [18F]-FDG PET/CT

Authors: Haojun Chen, M.D., Yimin Li, M.D., Hua Wu, M.D., Ph.D., Long Sun, M.D., Ph.D., Qin Lin, M.D., Ph.D., Long Zhao, M.D., Hanxiang An, M.D., Ph.D.

Published in: Strahlentherapie und Onkologie | Issue 2/2015

Abstract

Purpose

The purpose of this work was to investigate the prognostic value of response analysis using early 3’-deoxy-3’-[¹⁸F]-fluorothymidine (¹⁸F-FLT) PET/CT in esophageal squamous cancer patients and make a comparison with [¹⁸F]-fluorodeoxyglucose (¹⁸F-FDG) PET/CT.

Patients and materials

For 34 patients with esophageal squamous cell cancer, both ¹⁸F-FLT PET/CT and ¹⁸F-FDG PET/CT scans were performed at baseline (pre), 4 weeks after the start of radiotherapy or chemoradiotherapy (interim), and 2 weeks after therapy completion (final). SUV_max1, SUV_max2, and SUV_max3 represent SUV_max (SUV: standard uptake values) measured on the pre, interim, and final scans, respectively. GTV_FLT-PET and GTV_FDG-PET (GTV: gross tumor volume) were measured on the pre and interim scans. ΔSUV/ΔGTV represents the fractional changes of SUV_max/GTV between two different time points. PET parameters were evaluated for correlations with outcome.

Results

Regarding ¹⁸F-FLT PET/CT, according to receiver operating characteristic (ROC) curve analysis, parameters for predicting 2-year progression-free survival (PFS) and locoregional control (LRC) showed the highest area under curve (AUC) on interim ¹⁸F-FLT PET/CT scans (ΔSUV12, AUC of 0.812 for PFS, 0.775 for LRC, with a cutoff of 60 %; P = 0.008), compared with the parameters on pre and final scans. Patients with a ΔSUV12 greater than 60 %, who were defined as interim PET-negative group, were associated with better 2-year PFS and LRC than the interim PET-positive group (PFS: 70.6 % vs. 35.2 %, P = 0.025; LRC: 84.2 % vs 52.9, P = 0.046). In terms of ¹⁸F-FDG PET/CT, ΔSUV13 on the final 18F-FDG PET/CT scan demonstrated better prediction (AUC of 0.812 for PFS, 0.807 for LRC, with a cutoff of 75 %; P = 0.016) than the parameters on pre and interim scans. An SUV_max decrease ≥ 75 % on the final¹⁸F-FDG PET/CT scan was associated with better clinical outcome (PFS: 73.3 % vs. 36.8 %, P = 0.022; LRC: 86.7 % vs 52.6, P = 0.029). These correlations were most prominent in the subgroup of patients treated with chemoradiotherapy.

Conclusion

Early interim ¹⁸F-FLT PET/CT is a significant predictor of 2-year PFS and LRC, which is correlated better with early responses and late outcomes than interim ¹⁸F-FDG PET/CT in esophageal squamous cancer patients.

Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef

Semrau R, Herzog SL, Vallbohmer D et al (2012) Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlenther Onkol 188:226–232PubMedCrossRef

Westerterp M, van Westreenen HL, Reitsma JB et al (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review. Radiology 236:841–851PubMedCrossRef

Tixier F, Le Rest CC, Hatt M et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378PubMedCentralPubMedCrossRef

Essler M, Wantke J, Mayer B et al (2013) Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. Strahlenther Onkol 189:495–501PubMedCrossRef

Troost EG, Schinagl DA, Bussink J et al (2010) Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 51:66–76PubMedCrossRef

Arslan N, Miller TR, Dehdashti F et al (2002) Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4:301–310PubMedCrossRef

Jadvar H (2013) Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 40:5–10PubMedCentralCrossRef

Yang YJ, Ryu JS, Kim SY et al (2006) Use of 3’-deoxy-3’-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33:412–419PubMedCrossRef

10.

Herrmann K, Buck AK, Schuster T et al (2011) Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 52:690–696PubMedCrossRef

11.

Lee H, Kim SK, Kim YI et al (2014) Early determination of prognosis by interim 3’-deoxy-3’-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. J Nucl Med 55:216–222PubMedCrossRef

12.

Machulla H-J, Blocher A, Kuntzsch M et al (2000) Simplified labeling approach for synthesizing 3’-deoxy-3’-[18F] fluorothymidine ([18F] FLT). J Radioanal Nucl Chem 243:843–846CrossRef

13.

Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5:516–525PubMedCrossRef

14.

Withers HR, Taylor JM (1993) Critical volume model. Int J Radiat Oncol Biol Phys 25:151–152PubMedCrossRef

15.

Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. Strahlenther Onkol 188:666–670PubMedCrossRef

16.

Balermpas P, Bauer C, Fraunholz I et al (2014) Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlenther Onkol 190:256–262PubMedCrossRef

17.

Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef

18.

Murphy JD, La TH, Chu K et al (2011) Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys 80:514–521PubMedCentralPubMedCrossRef

19.

Castaldi P, Rufini V, Bussu F et al (2012) Can “early” and “late”18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 103:63–68PubMedCrossRef

20.

Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805PubMedCrossRef

21.

zum Buschenfelde CM, Herrmann, Schuster T et al (2011) (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 52:1189–1196PubMedCrossRef

22.

Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692–4698PubMedCrossRef

23.

Lin Q, Yang R, Sun L et al (2012) Biological response of nasopharyngeal carcinoma to radiation therapy: a pilot study using serial 18F-FDG PET/CT scans. Cancer Invest 30:528–536PubMedCrossRef

24.

Sohn HJ, Yang YJ, Ryu JS et al (2008) [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14:7423–7429PubMedCrossRef

25.

Hoeben BA, Troost EG, Span PN et al (2013) 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 54:532–540PubMedCrossRef

26.

Arens AI, Troost EG, Hoeben BA et al (2014) Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Eur J Nucl Med Mol Imaging 41:915–924PubMedCrossRef

27.

Schwarzenberg J, Czernin J, Cloughesy TF et al (2012) 3’-deoxy-3’-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29–36PubMedCentralPubMedCrossRef

28.

Yue J, Chen L, Cabrera AR et al (2010) Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med 51:528–534PubMedCrossRef

29.

Pastor C, Subtil JC, Sola J et al (2011) Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? Dis Colon Rectum 54:1141–1146PubMedCrossRef

Title: 3’-Deoxy-3’-[18F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer
Comparison with [18F]-FDG PET/CT
Authors: Haojun Chen, M.D.
Yimin Li, M.D.
Hua Wu, M.D., Ph.D.
Long Sun, M.D., Ph.D.
Qin Lin, M.D., Ph.D.
Long Zhao, M.D.
Hanxiang An, M.D., Ph.D.
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 2/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0744-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

3’-Deoxy-3’-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer

Comparison with [18F]-FDG PET/CT

Abstract

Purpose

Patients and materials

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and materials

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

Targeting of EGFR and HER2 with therapeutic antibodies and siRNA

Einfluss von Dosis und Fraktionierung bei der intensitätsmodulierten Rebestrahlung von Patienten mit Rezidiv eines Nasopharynxkarzinoms

Appreciation for Prof. Rolf Sauer on the occasion of the transferral of the editorship of “Strahlentherapie und Onkologie”

Warum lehnen Tumorpatienten eine kurative Strahlentherapie ab?

Evaluation of the time required for overhead tasks performed by physicians, medical physicists, and technicians in radiation oncology institutions

Comparison of 3D and 4D Monte Carlo optimization in robotic tracking stereotactic body radiotherapy of lung cancer